Medicus Pharma announces first patient treated in UAE SKNJCT-004 Phase 2 study

Medicus Pharma (MDCX) announced the enrollment of the first patient in United Arab Emirates SKNJCT-004 phase 2 clinical study, to non-invasively treat BCC of the skin. The study is expected to randomize thirty-six patients in six sites in UAE. In addition to Cleveland Clinic Abu Dhabi, the study is also expected to commence patient recruitment in Sheikh Shakbout Medical City, Burjeel Medical City, Rashid Hospital, Clemenceau Medical Center and American Hospital of Dubai. Insights Research Organization and Solutions, a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio company.